RxDoctor Payments Data

Ashley Skinner, NP

Nurse Practitioner · Carrollton, GANPI 1841866225

Payments from drug & device makers

$4,020in general payments, 2019–2025

Across 230 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$732
  • Boehringer Ingelheim$685
  • Lilly USA, LLC$293
  • Sanofi$217
  • Novo Nordisk$212
  • Takeda Pharmaceuticals U.S.A., Inc.$167
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$3,96399%
  • Education$571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,020 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$59,246
Medicare patients
331
Services billed
5,325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter609$515,041
Spiriva RespimatTiotropium Bromide101$76,129
Breo ElliptaFluticasone/Vilanterol108$66,510
Stiolto RespimatTiotropium Br/Olodaterol Hcl87$61,440
NucalaMepolizumab16$59,021
Breztri AerosphereBudesonide/Glycopyr/Formoterol72$56,705
Dupixent PenDupilumab14$52,314
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$30,517
Albuterol Sulfate HfaAlbuterol Sulfate643$26,427
MounjaroTirzepatide11$17,941
SymbicortBudesonide/Formoterol Fumarate50$16,954
Combivent RespimatIpratropium/Albuterol Sulfate16$11,582
Fluticasone-SalmeterolFluticasone Propion/Salmeterol45$11,184
Ventolin HfaAlbuterol Sulfate60$6,524
Fluticasone-VilanterolFluticasone/Vilanterol16$6,383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta$732$671,089779 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$685$149,152204 claims
AstraZenecaBreztri Aerosphere, Symbicort$95$73,659122 claims
Lilly USA, LLCMounjaro$293$17,94111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Carrollton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →